Role of the phytoestrogenic, pro-apoptotic and anti-oxidative properties of silymarin in inhibiting experimental benign prostatic hyperplasia in rats

Toxicology Letters

Volumn 219, Issue 2, 2013, Pages 160-169

  Atawia, Reem T ^a   Tadros, Mariane G ^a   Khalifa, Amani E ^a   Mosli, Hisham A ^b   Abdel Naim, Ashraf B ^a  

^a Ain Shams University   (Egypt)

^b Aziz University   (Saudi Arabia)

Author keywords

Apoptosis; Estrogen receptors; Oxidative stress; Prostatic hyperplasia; Silymarin

Indexed keywords

ANDROGEN RECEPTOR; CASPASE 3; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLINE; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PROTEIN BAX; PROTEIN BCL XL; SILYMARIN; TESTOSTERONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BODY WEIGHT; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG INHIBITION; ENZYME ACTIVITY; HISTOPATHOLOGY; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATE WEIGHT; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTIOXIDANTS; APOPTOSIS; BODY WEIGHT; CASPASE 3; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; IMMUNOHISTOCHEMISTRY; MALE; NF-KAPPA B; ORGAN SIZE; OXIDATIVE STRESS; PHYTOESTROGENS; PROLIFERATING CELL NUCLEAR ANTIGEN; PROSTATE; PROSTATIC HYPERPLASIA; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; RNA, MESSENGER; SILYMARIN; TESTOSTERONE;

RATTUS;

EID: 84876320605     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2013.03.002     Document Type: Article

References (54)

1. Aebi H. Catalase in vitro. Methods in Enzymology 1984, 105:121-126.
2. Agarwal R. Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents. Biochemical Pharmacology 2000, 60:1051-1059.
3. Ali M.I., Kondreddi H.D., Veeresh B. Protective effect of 2-hydroxy-4-methoxy benzoic acid on testosterone induced benign prostatic hyperplasia in Wister rats. European Journal of Pharmacology 2013, 698:397-403.
4. Baeuerle P.A., Baltimore D. NF-kappa B: ten years after. Cell 1996, 87:13-20.
5. Baeuerle P.A., Henkel T. Function and activation of NF-kappa B in the immune system. Annual Review of Immunology 1994, 12:141-179.
6. Barone M., Tanzi S., Lofano K., Scavo M.P., Pricci M., Demarinis L., Papagni S., Guido R., Maiorano E., Ingravallo G., Comelli M.C., Francavilla A., Di Leo A. Dietary-induced ERbeta upregulation counteracts intestinal neoplasia development in intact male ApcMin/+ mice. Carcinogenesis 2010, 31:269-274.
7. Bentires-Alj M., Dejardin E., Viatour P., Van Lint C., Froesch B., Reed J.C., Merville M.P., Bours V. Inhibition of the NF-kappa B transcription factor increases Bax expression in cancer cell lines. Oncogene 2001, 20:2805-2813.
8. Beutler E., Duron O., Kelly B.M. Improved method for the determination of blood glutathione. The Journal of Laboratory and Clinical Medicine 1963, 61:882-888.
9. Bodker A., Bruun J., Balslev E., Iversen H.G., Meyhoff H.H., Andersson K.E. Estrogen receptors in the human male prostatic urethra and prostate in prostatic cancer and benign prostatic hyperplasia. Scandinavian Journal of Urology and Nephrology 1999, 33:237-242.
10. Chatterjee B. The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer. Molecular and Cellular Biochemistry 2003, 253:89-101.
11. Chen C., Edelstein L.C., Gelinas C. The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Molecular and Cellular Biology 2000, 20:2687-2695.
12. Ciocca D.R., Puy L.A., Edwards D.P., Adams D.J., McGuire W.L. The presence of an estrogen-regulated protein detected by monoclonal antibody in abnormal human endometrium. The Journal of Clinical Endocrinology and Metabolism 1985, 60:137-143.
13. Deep G., Gangar S.C., Oberlies N.H., Kroll D.J., Agarwal R. Isosilybin A induces apoptosis in human prostate cancer cells via targeting Akt, NF-kappaB, and androgen receptor signaling. Molecular Carcinogenesis 2010, 49:902-912.
14. Deep G., Oberlies N.H., Kroll D.J., Agarwal R. Isosilybin B causes androgen receptor degradation in human prostate carcinoma cells via PI3K-Akt-Mdm2-mediated pathway. Oncogene 2008, 27:3986-3998.
15. Dhanalakshmi S., Singh R.P., Agarwal C., Agarwal R. Silibinin inhibits constitutive and TNFalpha-induced activation of NF-kappaB and sensitizes human prostate carcinoma DU145 cells to TNFalpha-induced apoptosis. Oncogene 2002, 21:1759-1767.
16. Donnell R.F. Benign prostate hyperplasia: a review of the year's progress from bench to clinic. Current Opinion in Urology 2011, 21:22-26.
17. Donovan M., Cotter T.G. Control of mitochondrial integrity by Bcl-2 family members and caspase-independent cell death. Biochimica et Biophysica Acta 2004, 1644:133-147.
18. Engel F.B., Hauck L., Boehm M., Nabel E.G., Dietz R., von Harsdorf R. p21(CIP1) controls proliferating cell nuclear antigen level in adult cardiomyocytes. Molecular and Cellular Biology 2003, 23:555-565.
19. Glienke W., Dolgova Y., Muller I., Grosch S., Binder J., Geisslinger G., Jonas D. Induction of apoptosis in human prostate stromal cells by 4-hydroxytamoxifen: an alternative therapy for benign prostate hyperplasia. World Journal of Urology 2004, 22:452-456.
20. Harkonen P.L., Makela S.I. Role of estrogens in development of prostate cancer. The Journal of Steroid Biochemistry and Molecular Biology 2004, 92:297-305.
21. Helguero L.A., Faulds M.H., Gustafsson J.A., Haldosen L.A. Estrogen receptors alfa (ERalpha) and beta (ERbeta) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11. Oncogene 2005, 24:6605-6616.
22. Huo J.X., Metz S.A., Li G.D. p53-independent induction of p21(waf1/cip1) contributes to the activation of caspases in GTP-depletion-induced apoptosis of insulin-secreting cells. Cell Death and Differentiation 2004, 11:99-109.
23. Johnson J.J., Syed D.N., Suh Y., Heren C.R., Saleem M., Siddiqui I.A., Mukhtar H. Disruption of androgen and estrogen receptor activity in prostate cancer by a novel dietary diterpene carnosol: implications for chemoprevention. Cancer prevention Research (Philadelphia, Pa.) 2010, 3:1112-1123.
24. Katiyar S.K., Roy A.M., Baliga M.S. Silymarin induces apoptosis primarily through a p53-dependent pathway involving Bcl-2/Bax, cytochrome c release, and caspase activation. Molecular Cancer Therapeutics 2005, 4:207-216.
25. Lee K.L., Peehl D.M. Molecular and cellular pathogenesis of benign prostatic hyperplasia. Journal of Urology 2004, 172:1784-1791.
26. Lee T.L., Yeh J., Friedman J., Yan B., Yang X., Yeh N.T., Van Waes C., Chen Z. A signal network involving coactivated NF-kappaB and STAT3 and altered p53 modulates BAX/BCL-XL expression and promotes cell survival of head and neck squamous cell carcinomas. International Journal of Cancer 2008, 122:1987-1998.
27. Lytton B., Emery J.M., Harvard B.M. The incidence of benign prostatic obstruction. Journal of Urology 1968, 99:639-645.
28. Maggi C.A., Manzini S., Giuliani S., Meli A. Infravesical outflow obstruction in rats: a comparison of two models. General pharmacology 1989, 20:345-349.
29. McPherson S.J., Ellem S.J., Simpson E.R., Patchev V., Fritzemeier K.H., Risbridger G.P. Essential role for estrogen receptor beta in stromal-epithelial regulation of prostatic hyperplasia. Endocrinology 2007, 148:566-574.
30. Mihara M., Uchiyama M. Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Analytical Biochemistry 1978, 86:271-278.
31. Muzes G., Deak G., Lang I., Nekam K., Niederland V., Feher J. Effect of silimarin (Legalon) therapy on the antioxidant defense mechanism and lipid peroxidation in alcoholic liver disease (double blind protocol). Orvosi Hetilap 1990, 131:863-866.
32. Nicholson D.W., Ali A., Thornberry N.A., Vaillancourt J.P., Ding C.K., Gallant M., Gareau Y., Griffin P.R., Labelle M., Lazebnik Y.A., Munday N.A., Raju S.M., Smulson M.E., Yamin T., Yu V.L., Miller D.K. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995, 376:37-43.
33. Pace G., Di Massimo C., De Amicis D., Corbacelli C., Di Renzo L., Vicentini C., Miano L., Tozzi Ciancarelli M.G. Oxidative stress in benign prostatic hyperplasia and prostate cancer. Urologia Internationalis 2010, 85:328-333.
34. Pahl H.L. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999, 18:6853-6866.
35. Papaliagkas V., Anogianaki A., Anogianakis G., Ilonidis G. The proteins and the mechanisms of apoptosis: a mini-review of the fundamentals. Hippokratia 2007, 11:108-113.
36. Pawlicki B., Zielinski H., Dabrowski M. Role of apoptosis and chronic prostatitis in the pathogenesis of benign prostatic hyperplasia. Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego 2004, 17:307-310.
37. Rick F.G., Schally A.V., Block N.L., Nadji M., Szepeshazi K., Zarandi M., Vidaurre I., Perez R., Halmos G., Szalontay L. Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:3755-3760.
38. Royuela M., de Miguel M.P., Bethencourt F.R., Sanchez-Chapado M., Fraile B., Arenas M.I., Paniagua R. Estrogen receptors alpha and beta in the normal, hyperplastic and carcinomatous human prostate. The Journal of Endocrinology 2001, 168:447-454.
39. Saha I., Chatterjee A., Mondal A., Maiti B.R., Chatterji U. Arecoline augments cellular proliferation in the prostate gland of male Wistar rats. Toxicology and Applied Pharmacology 2011, 255:160-168.
40. Sandhu J.S., Te A.E. The role of 5-alpha-reductase inhibition as monotherapy in view of the MTOPS data. Current Urology Reports 2004, 5:274-279.
41. Seidlová-Wuttke D., Becker T., Christoffel V., Jarry H., Wuttke W. Silymarin is a selective estrogen receptor beta (ERbeta) agonist and has estrogenic effects in the metaphysis of the femur but no or antiestrogenic effects in the uterus of ovariectomized (ovx) rats. The Journal of Steroid Biochemistry and Molecular Biology 2003, 86:179-188.
42. Soto C., Recoba R., Barron H., Alvarez C., Favari L. Silymarin increases antioxidant enzymes in alloxan-induced diabetes in rat pancreas. Comparative Biochemistry and Physiology. Toxicology & Pharmacology: CBP 2003, 136:205-212.
43. Stanbrough M., Leav I., Kwan P.W., Bubley G.J., Balk S.P. Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:10823-10828.
44. Takeda H., Nakamoto T., Kokontis J., Chodak G.W., Chang C. Autoregulation of androgen receptor expression in rodent prostate: immunohistochemical and in situ hybridization analysis. Biochemical and Biophysical Research Communications 1991, 177:488-496.
45. Thiyagarajan M., Kaul C.L., Ramarao P. Enhancement of alpha-adrenoceptor-mediated responses in prostate of testosterone-treated rat. European Journal of Pharmacology 2002, 453:335-344.
46. Trukhacheva E., Lin Z., Reierstad S., Cheng Y.H., Milad M., Bulun S.E. Estrogen receptor (ER) beta regulates ERalpha expression in stromal cells derived from ovarian endometriosis. The Journal of Clinical Endocrinology and Metabolism 2009, 94:615-622.
47. Uygur M.C., Gur E., Arik A.I., Altug U., Erol D. Erectile dysfunction following treatments of benign prostatic hyperplasia: a prospective study. Andrologia 1998, 30:5-10.
48. van Breemen R.B., Sharifi R., Viana M., Pajkovic N., Zhu D., Yuan L., Yang Y., Bowen P.E., Stacewicz-Sapuntzakis M. Antioxidant effects of lycopene in African American men with prostate cancer or benign prostate hyperplasia: a randomized, controlled trial. Cancer prevention Research (Philadelphia, Pa.) 2011, 4:711-718.
49. Waga S., Hannon G.J., Beach D., Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994, 369:574-578.
50. Wang C.Y., Mayo M.W., Korneluk R.G., Goeddel D.V., Baldwin A.S. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998, 281:1680-1683.
51. Weihua Z., Lathe R., Warner M., Gustafsson J.A. An endocrine pathway in the prostate, ERbeta, AR, 5alpha-androstane-3beta, 17beta-diol, and CYP7B1, regulates prostate growth. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:13589-13594.
52. Wellington K., Jarvis B. Silymarin: a review of its clinical properties in the management of hepatic disorders. BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy 2001, 15:465-489.
53. Young, C., Xing, N., 2004. Methods and compositions for inhibiting the proliferation of prostate cancer cells. U.S. Patent No. 6,680,342.
54. Yu S., Wong Y.C., Wang X.H., Ling M.T., Ng C.F., Chen S., Chan F.L. Orphan nuclear receptor estrogen-related receptor-beta suppresses in vitro and in vivo growth of prostate cancer cells via p21(WAF1/CIP1) induction and as a potential therapeutic target in prostate cancer. Oncogene 2008, 27:3313-3328.